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INTRODUCTION
Prostate cancer is a common malignancy 
and a common cause of cancer-related 
death in men across many healthcare 
systems globally.1–5 The role of screening 
for prostate cancer using prostate-specific 
antigen (PSA) testing in asymptomatic men 
has been evaluated in several randomised 
controlled trials (RCTs),6–10 but results are 
difficult to assimilate into a cohesive narrative 
regarding the risks and benefits of such 
screening. Several RCTs also have major 
methodological limitations, mostly due to 
contamination of the control groups — that 
is, men randomised to a non-screening arm 
who then undergo opportunistic screening 
tests.11–13 
The largest trial to date, the Cluster 
Randomised Trial of PSA Testing for 
Prostate Cancer (CAP), found no statistically 
significant difference in prostate cancer-
specific mortality between controls and those 
in the study arm who were offered low-
intensity screening with a one-off PSA test.9 
However, the degree of contamination in the 
control arm was not empirically assessed; 
this is particularly important, given that the 
intervention arm’s screening uptake was only 
36%. If the control arm of the CAP trial was 
substantially contaminated, this could have 
biased the results, potentially masking the 
true effect of the study intervention.
Although no formal screening programme 
exists in the UK, men may opt into screening 
as they can access PSA testing via shared 
decision making with their GP. The uptake 
of PSA testing and trends therein for some 
countries, particularly the US, has been 
relatively well characterised in several 
studies;14–16 the uptake of PSA testing, in 
general, in the UK has been studied in several 
cross-sectional17–19 and longitudinal studies,20 
but these reports are limited as they tend to 
have narrow timeframes of interest, divergent 
geographical foci, restricted evaluation of 
sociodemographic associations with PSA 
testing uptake, and/or do not attempt to 
distinguish between men having PSA tests to 
investigate symptoms indicative of prostatic 
hypertrophy and men who are asymptomatic 
and having PSA tests to detect early-stage 
cancer. 
In this study, a comprehensive analysis of 
the uptake of PSA testing across England 
was undertaken using linked datasets, and 
the uptake of opportunistic PSA screening in 
men who were asymptomatic was analysed. 
The primary objective was to quantify the 
cumulative incidence of PSA testing and 
opportunistic PSA screening between 1998 
and 2017; the secondary objectives comprised 
identifying associations between PSA 
testing/opportunistic PSA screening rates 
and sociodemographic and protective/risk 
factors for prostate cancer.21,22 Furthermore, 
population-based estimates of the potential 
pre-randomisation testing and control-arm 
contamination of the CAP trial, based on 
time-period- and age-group-restricted 
analyses of the cohort, were derived. 
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undertaken using the QResearch database.
Method
Eligible men were followed for up to 19 years. 
Rates of PSA testing and opportunistic PSA 
screening were calculated; Cox regression was 
used to estimate associations.
Results
The cohort comprised 2 808 477 men, of 
whom 631 426 had a total of 1 720 855 PSA 
tests. The authors identified that 410 724 men 
had opportunistic PSA screening. Cumulative 
proportions of uptake of opportunistic screening 
in the cohort were 9.96% at 5 years’, 22.71% at 
10 years’, and 44.13% at 19 years’ follow-up. 
The potential rate of contamination in the CAP 
control arm was estimated at 24.50%.
Conclusion
A substantial number of men in England opt 
in to opportunistic prostate cancer screening, 
despite uncertainty regarding its efficacy and 
harms. The rate of opportunistic prostate 
cancer screening in the population is likely to 
have contaminated the CAP trial, making it 
difficult to interpret the results.
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METHOD
A cohort study of men identified from the 
QResearch database (version 42) was 
undertaken. The database has accrued 
anonymised data on approximately 28 million 
patients over 25 years from 1457 UK-based 
general practices that implement the 
Egton Medical Information Systems (EMIS) 
computer system; it is representative of the 
UK population.22–24 The extracted dataset 
(2.8 million patients) had full linkage to: 
the Office for National Statistics’ mortality 
records; Hospital Episode Statistics records 
for dates of prostate biopsies and operations/
treatment; and Public Health England cancer 
registration data regarding the date of a 
prostate cancer diagnosis. 
Individual practices were eligible for 
inclusion if they contributed data within the 
study period of interest — namely, between 
1 January 1998 and 31 March 2017. Men 
aged 40–75 years at study entry were eligible 
for inclusion. Entry to the open cohort was 
permitted when:
• men had no previous PSA test and no 
previous prostate disease diagnosis/
investigation/treatment;
• men had at least 12 months’ registration 
with their practice; 
• men had had their 40th birthday; and 
• the practice had been using EMIS for at 
least 12 months.
The latest of these dates was defined as 
the cohort entry date. Men were excluded if 
they had:
• a pre-existing diagnosis of prostate cancer; 
• prostatic hypertrophy;
• previously had a prostatectomy;
• previously had anti-androgen therapy; or 
• other prostate-directed surgery or biopsy 
recorded prior to the cohort entry date 
recorded on any of the linked data sources.
Data regarding multiple risk factors for 
prostate cancer (including age, ethnicity, 
family history of prostate cancer, smoking 
status, and comorbidities) were extracted, as 
well as records of PSA tests and dates, Read 
codes for urinary symptoms (and dates), and 
cause of death.22 
Given the age groups eligible for inclusion 
and the years in which the trial was 
conducted, the same cohort of men was used 
for the main analyses; however, a subgroup 
of the cohort was used for analyses relevant 
to the CAP trial. This sub-cohort comprised 
men aged 50–69 years.
Study outcomes were PSA testing (any 
man having a PSA test) and opportunistic 
PSA screening, which was defined as a PSA 
test being performed on men with no Read-
coded urinary symptoms recorded at any 
time prior to the test.
Statistical analysis
Kaplan–Meier failure functions were used 
to estimate the cumulative risks of having 
at least one PSA test and at least one 
opportunistic screening PSA test during 
follow-up (1998–2017). For the former, follow-
up was calculated from the cohort entry date 
to the date of the first PSA test or censoring 
(cohort exit due to earliest of study end date, 
death, transfer out of practice, or diagnosis of 
prostate cancer). For the latter, follow-up was 
calculated from entry to censoring (cohort 
exit due to study end date, death, leaving the 
practice, or having a PSA test in the context 
of urinary symptoms suggestive of prostate 
pathology as per the aforementioned Read 
codes). There was no upper age limit for 
censoring. 
Failure functions for both endpoints were 
stratified by ethnicity, body mass index (BMI) 
categories, Townsend deprivation quintile, 
smoking status, diabetes, geographical 
region, bipolar disorder or schizophrenia, 
and recorded family history of prostate 
cancer. Log-rank tests were used to identify 
significant differences between strata of 
covariates. Person-year methodology was 
used to calculate age-group-specific rates 
of PSA testing and opportunistic screening. 
Trends in annual rates of men starting 
PSA testing and opportunistic screening 
between 1998 and 2016 (complete years) 
How this fits in 
Men in the UK are generally regarded as 
having a low uptake of prostate cancer 
screening, but the largest ever screening 
trial, the Cluster Randomised Trial of 
PSA [prostate-specific antigen] Testing 
for Prostate Cancer, was based in the 
UK. In this observational study, to the 
authors’ knowledge, the largest and 
most comprehensive assessment of 
opportunistic prostate cancer screening 
behaviours in England was performed in 
a cohort study of >2.8 million men. It was 
found that a sizeable proportion of men opt 
in to opportunistic PSA screening every year 
The results suggest that this ‘screening on 
demand’ may have significant implications. 
For example, nuanced interpretation of 
trials in UK men may be needed, and 
rates of opportunistic screening may 
contextualise observed trends in prostate 
cancer diagnosis and outcomes. 
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were analysed by calculating the percentage 
of men, entered in each calendar year, 
who were undergoing their first PSA test. 
Temporal trends in testing and opportunistic 
screening were assessed using annual 
percentage changes (APC) calculated using 
Joinpoint regression analyses.25,26 The 
parametric method was used to calculate 
APC confidence intervals (CIs). 
Pre-randomisation opportunistic 
screening was estimated in the 3 years prior 
to the CAP trial by identifying a subgroup 
of males aged 50–69 years in the study 
cohort between 1 January 1998 and 31 
December 2000; Kaplan–Meier failure 
functions were utilised. The potential rate 
of contamination of the control arm of the 
CAP trial was estimated by calculating 
the cumulative risks of having a PSA test 
deemed to be for opportunistic screening 
in men aged 50–69 years who entered 
the cohort between 1 January 2001 and 
31 March 2016. The dates and age groups 
for these sub-analyses correspond to the 
timeframes and inclusion criteria of the CAP 
trial respectively. Follow-up and censoring 
were as outlined above.
Cox proportional-hazards models were 
utilised in the whole study cohort to ascertain 
independent predictors of undergoing a PSA 
test and opportunistic PSA screening (as 
complete case analyses). Results are reported 
as adjusted hazard ratios (HRs), with 95% CIs 
and P-values. The proportional-hazards 
assumption was assessed. All statistically 
significant risk factors (P<0.01) identified in 
univariate analyses were included in a single 
multivariable Cox regression model.
Joinpoint regression analyses utilised 
Joinpoint Regression Program 4.6.0; all other 
statistical analyses were executed using Stata 
(version 15.1). The significance level was set 




The cohort that was initially extracted 
comprised 3 211 276 men aged 40–74 years 
from a total of 1457 general practices in 
England, which represented 19.60% of all 
the 7435 practices in England as of June 
2017. After exclusions, the final study cohort 
comprised 2 808 477 men who had not 
had a previous PSA test (total follow-up: 
21 569 176 person-years). Median follow-
up was 5.9 years (interquartile range [IQR] 
2.2–13.3 years), with a maximum of 19 years. 
The sociodemographic characteristics of the 
study cohort are summarised in Table 1; in 
brief, 54.75% were white (36.66% had no 
recorded ethnicity) and 0.27% had a recorded 
family history of prostate cancer. 
During follow-up, there were 50 791 
diagnoses of benign prostatic hypertrophy 
(1.81% of the total patient cohort), 52 811 
diagnoses of prostate cancer (1.88% of the 
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Table 1. Sociodemographic characteristics of the final study cohort 
(N = 2 808 477)
Characteristic n (%)
Ethnicity
 White 1 537 660 (54.75)
 Indian  44 693 (1.59)
 Pakistani 25 229 (0.90)
 Bangladeshi  18 487 (0.66)
 Other Asian  27 600 (0.98)
 Caribbean  24 835 (0.88)
 Black African  42 405 (1.51)
 Chinese 9785 (0.35)
 Other 48 299 (1.72)
 Not recorded  1 029 484 (36.66)
Geographical region 
 East Midlands 146 179 (5.20)
 East of England  182 864 (6.51)
 London 584 489 (20.81)
 North East  101 938 (3.63)
 North West 445 295 (15.86)
 South Central  365 111 (13.00)
 South East  230 681 (8.21)
 South West  312 760 (11.14)
 West Midlands  298 113 (10.61)
 Yorkshire & Humber  141 047 (5.02)
BMI categorya 
 Underweight (<18.5 kg/m2) 22 770 (0.98)
 Healthy weight (18.5–24.9 kg/m2) 731 913 (31.45)
 Overweight (25.0–29.9 kg/m2) 1 015 095 (43.62)
 Obese (30.0–39.9 kg/m2) 521 124 (22.39)
 Severely obese (≥40.0 kg/m2) 36 102 (1.55)
Deprivation quintileb 
 1 (most affluent) 548 305 (19.58)
 2 550 816 (19.67)
 3 558 866 (19.96)
 4 565 215 (20.19)
 5 (most deprived) 576 657 (20.60) 
Smoking statusc 
 Non-smoker  1 212 254 (47.00)
 Ex-smoker  633 556 (24.57)
 Light smoker (1–9/day) 391 036 (15.16)
 Moderate smoker (10–19/day) 170 700 (6.62)
 Heavy smoker (≥20/day) 171 544 (6.65)
Diabetic status 
 No diabetes  2 482 092 (88.38)
 Type 1 diabetes  10 070 (0.36)
 Type 2 diabetes  316 315 (11.26)
Family history of prostate cancer
 Yes 7641 (0.27)
 No 2 800 836 (99.73)
Diagnosis of bipolar disorder or schizophrenia
 Yes 31 717 (1.13)
 No 2 776 760 (98.87)
an = 2 327 004 (82.9% of cohort). bn = 2 799 859 (99.6% of cohort). cn = 2 579 090 (91.8% of cohort). BMI = body mass 
index.
total patient cohort), and 3115 deaths from 
prostate cancer (0.11% of the total patient 
cohort). 
PSA testing 
In total, 631 426 men (22.48%) had at least 
one PSA test during the follow-up period 
(Table 2) (total tests = 1 720 855). The 
estimated cumulative risks of men having 
at least one PSA test were 2.28% at 1 year’s 
follow-up (95% CI = 2.23 to 2.32), 13.36% at 
5 years’ follow-up (95% CI = 13.32 to 13.41), 
29.71% at 10 years’ follow-up (95% CI = 29.64 
to 29.79), and 55.25% (95% CI = 55.12 to 55.38) 
at 19 years’ follow-up (data not shown). There 
was a clear association between increasing 
age and higher rates of first PSA testing 
(Table 2).
The cumulative risks of PSA testing 
when stratified by ethnicity, BMI, Townsend 
deprivation level, smoking status, diabetes 
status, geographical region, and family 
history of prostate cancer are shown in 
Figure 1. In univariate analyses, there 
were statistically significant differences in 
the cumulative risk of PSA testing when 
stratified (all P<0.0001, log-rank test). The 
adjusted HRs of multivariable analyses of 
associations with PSA testing uptake are 
given in Table 3. 
For 1998–2016, annual rates of first PSA 
testing ranged between 0.76% and 4.36%. 
Joinpoint regression analyses demonstrated 
statistically significant changes in the trends 
of PSA testing uptake: between 1998 and 
2001, the APC was +41.71% (95% CI = 26.82 
to 58.44, P<0.01); between 2001 and 2004, it 
was +14.83% (95% CI = 1.52 to 29.87, P<0.01); 
between 2004 and 2009, it was +5.23% (95% 
CI = 1.82 to 8.85, P<0.01); and between 2009 
and 2016, it was –2.24% (95% CI = –3.61 to 
–0.82, P<0.01).
Opportunistic PSA screening
The authors identified 410 724 men who were 
deemed as having undergone opportunistic 
screening for prostate cancer (Table 2), 
representing 14.62% of all men in the study 
cohort; as such, 65.04% of all first PSA tests 
in the study period [410 724 out of 631 426] 
were deemed to be for screening.
The estimated cumulative risks of men 
undergoing at least one opportunistic 
screening test were 1.67% (95% CI = 1.66 
to 1.69) at 1 year’s follow-up, 9.96% (95% 
CI = 9.92 to 10.01) at 5 years’ follow-up, 22.70% 
(95% CI = 22.62 to 22.77) at 10 years’ follow-
up, and 44.13% (95% CI = 43.99 to 44.27) at 
19 years’ follow-up. The rates of opportunistic 
PSA testing increased with increasing age 
(Table 2). The cumulative risks of undergoing 
a screening PSA test were statistically 
significantly associated with age, ethnicity 
(highest in Caribbean males), smoking 
status, positive diabetic status, geographical 
region, and positive family history of prostate 
cancer in univariate analysis (all P<0.0001, 
log-rank test, Figure 2). Table 3 demonstrates 
the adjusted HRs in multivariable analyses 
of associations with opportunistic screening 
uptake. There were significant associations 
with deprivation (inverse association), 
positive family history of prostate cancer, 
and increasing age. For example, men with 
a positive recorded family history of prostate 
cancer were over three times as likely to 
undergo an opportunistic screening test (HR 
3.47, 95% CI = 3.35 to 3.50).
Annual percentages for men starting 
opportunistic prostate screening ranged 
between 0.46% and 2.87%. In Joinpoint 
analyses, the APC in screening uptake 
between 1998 and 2004 was +24.73% [95% 
CI = 15.71 to 24.46, P<0.01); between 2004 
and 2014, it was 2.14% [95% CI = –0.32 to 
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Table 2. Age-specific rates per 1000 person-years in men undertaking their first PSA test for any 
indication and in men undergoing opportunistic screening
 PSA testing  Opportunistic PSA screening
 Having first PSA test PSA testing rate per  Having first Screening rate per  
Age group (any indication), n 1000 person-years 95% CI screening test, n 1000 person-years 95% CI
40–49 years 51 883 11.86 11.76 to 11.96 36 564 8.36 8.27 to 8.44
50–59 years 203 023 31.05 30.92 to 31.19 139 656 21.36 21.25 to 21.47
60–69 years 225 227 51.33 51.33 to 51.54 143 248 32.65 32.48 to 32.82
70–79 years 129 470 61.39 61.39 to 61.73 77 762 36.87 36.61 to 37.13
80–89 years 21 546 68.65 67.74 to 69.58 13 347 42.53 41.82 to 43.26
90–100 years 277 63.25 56.22 to 71.15 147 39.73 34.24 to 46.10
Overall  631 426 35.62  35.53 to 35.79 410 724 23.17 23.10 to 23.24
CI = confidence interval. PSA = prostate-specific antigen.
4.54%], P>0.05). Between 2014 and 2016, 
there was a statistically significant decline in 
screening uptake, with an APC of –29.41% 
(95% CI = –49.91 to –0.54%, P<0.01). 
Throughout this whole period of interest, the 
average APC was +4.73% [95% CI = 0.41 to 
9.24%].
Estimates of potential contamination
In total, 585 166 men aged 50–69 years 
were identified between 1 January 1998 
and 31 December 2000 (3 years preceding 
the CAP trial start date in 2001); of these, 
13 580 (2.32%) underwent at least one PSA 
screening test during that period (pre-
randomisation screening estimate). To 
estimate control-arm contamination, the 
authors identified men aged 50–69 years 
during the period of the CAP trial (2001–2016) 
— that is, those men who may have been 
eligible for inclusion. Of the 848 959 men 
identified, 208 041 (24.50%) had undergone 
at least one PSA screening test during the 
trial period (2001–2016) — the calculated 
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Figure 1. Kaplan–Meier failure functions for factors 
associated with PSA testing uptake.
BMI = body mass index. PSA = prostate-specific 
antigen.
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cumulative risk of undergoing screening was 
10% at 5 years’ follow-up, 23% at 10 years’ 
follow-up, and 36% at 15 years’ follow-up 
(2001–2016).
The influence of the CAP trial on the 
authors’ CAP-focused results — the study 
period was intentionally identical and some 
men in the cohort for the study presented 
Table 3. Cox regression analyses for PSA testing uptake and opportunistic screening uptake in members of 
the study cohort for whom data were complete (n = 2 305 998)a
  PSA testing   Opportunistic PSA screening
Characteristic Adjusted HRa  95% CI P-value Adjusted HR 95% CI P-value
Age (per 1-year increase) 1.04 1.04 to 1.04 <0.0001 1.04 1.04 to 1.04 <0.0001
Townsend deprivation quintile
 1 (most affluent) 1.00   1.00
 2 0.95 0.94 to 0.96 <0.0001 0.94 0.94 to 0.95 <0.0001
 3 0.88 0.88 to 0.89 <0.0001 0.87 0.86 to 0.88 <0.0001
 4 0.82 0.81 to 0.82 <0.0001 0.79 0.78 to 0.80 <0.0001
 5 (most deprived) 0.74 0.73 to 0.74 <0.0001 0.70 0.69 to 0.71 <0.0001
Ethnicity
 White 1.00   1.00
 Indian 1.14 1.12 to 1.17 <0.0001 1.16 1.13 to 1.18 <0.0001
 Pakistani 1.20 1.16 to 1.23 <0.0001 1.12 1.08 to 1.17 <0.0001
 Bangladeshi 1.17 1.13 to 1.21 <0.0001 0.99 0.94 to 1.05 0.729
 Other Asian 1.15 1.12 to 1.19 <0.0001 1.11 1.07 to 1.15 <0.0001
 Caribbean  1.60 1.57 to 1.64 <0.0001 1.55 1.51 to 1.60 <0.0001
 Black African  1.44 1.40 to 1.48 <0.0001 1.30 1.26 to 1.35 <0.0001
 Chinese 0.84 0.79 to 0.86 <0.0001 0.80 0.75 to 0.86 <0.0001
 Other 1.33 1.26 to 1.40 <0.0001 1.28 1.24 to 1.32 <0.0001
 Not recorded 0.75 0.74 to 0.75 <0.0001 0.76 0.75 to 0.76 <0.0001
Smoking status
 Non-smoker 1.00   1.00
 Ex-smoker 1.01 1.01 to 1.02 0.003 0.99 0.98 to 0.99 <0.0001
 Light smoker 0.87 0.86 to 0.88 <0.0001 0.84 0.83 to 0.85 <0.0001
 Moderate smoker 0.81 0.80 to 0.82 <0.0001 0.78 0.77 to 0.79 <0.0001
 Heavy smoker 0.80 0.79 to 0.81 <0.0001 0.76 0.75 to 0.77 <0.0001
Family history of prostate cancer
 No  1.00   1.00
 Yes 3.10 3.00 to 3.19 <0.0001 3.47 3.35 to 3.60 <0.0001
Diabetes status
 No diabetes 1.00   1.00
 Type 1 diabetes 0.87 0.83 to 0.92 <0.0001 0.47 0.43 to 0.51 <0.0001
 Type 2 diabetes 0.98 0.97 to 0.99 <0.0001 0.83 0.82 to 0.84 <0.0001
BMI category 
 Underweight (<18.5 kg/m2) 1.00   1.00
 Healthy weight (18.5–24.9 kg/m2) 1.09 1.05 to 1.12 <0.0001 1.03 0.99 to 1.06 0.153
 Overweight (25.0–29.9 kg/m2) 1.15 1.12 to 1.18 <0.0001 1.07 1.01 to 1.11 <0.0001
 Obese (3.00–39.9 kg/m2) 1.15 1.12 to 1.19 <0.0001 1.04 1.01 to 1.08 0.019
 Severely obese (≥40 kg/m2) 1.12 1.08 to 1.16 <0.0001 0.98 0.93 to 1.02 0.276
Geographical region 
 East Midlands 1.00   1.00
 East of England  1.04 1.02 to 1.05 <0.0001 1.07 1.05 to 1.09 <0.0001
 London 1.25 1.23 to 1.27 <0.0001 1.34 1.32 to 1.37 <0.0001
 North East  0.85 0.83 to 0.86 <0.0001 0.86 0.84 to 0.87 <0.0001
 North West  1.12 1.10 to 1.13 <0.0001 1.12 1.11 to 1.14 <0.0001
 South Central  1.14 1.13 to 1.16 <0.0001 1.21 1.19 to 1.23 <0.0001
 South East  1.41 1.39 to 1.43 <0.0001 1.46 1.44 to 1.49 <0.0001
 South West  1.11 1.07 to 1.10 <0.0001 1.12 1.10 to 1.14 <0.0001
 West Midlands  1.15 1.09 to 1.16 <0.0001 1.20 1.18 to 1.22 <0.0001
 Yorkshire & Humber  0.91 0.89 to 0.93 <0.0001 0.90 0.88 to 0.91 <0.0001
aAll significant risk factors identified in univariate analyses were included in a single Cox regression model, which is adjusted for all the other variables presented in the above table. 
BMI = body mass index. CI = confidence interval. HR = hazards ratio. PSA = prostate-specific antigen.
here may have been included in the CAP 
trial. Such influence, however, should 
be minimal as, although 67 313 men in 
the CAP trial arm underwent screening,9 
the authors identified 208 041 men aged 
50–69 years who had undergone at least 
one screening test during the CAP trial’s 
follow-up period. Assuming the almost 
impossible scenario that all screened men 
from the CAP trial (QResearch does not 
cover Cardiff) were included, the estimate 
of opportunistic screening in the remainder 
is 16.58% (140 728/848 959). Even in this 
overestimation of the worst-case scenario, 
a contamination rate of close to 20% can be 
calculated. The CAP trial power calculations 




To the authors’ knowledge, this is not only 
the largest study ever to report on the 
rates of PSA testing and opportunistic PSA 
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Figure 2. Kaplan–Meier failure functions for factors 
associated with opportunistic prostate cancer screening 
uptake. 
BMI = body mass index. BPAD = bipolar affective 
disorder.
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screening in the UK population, but also the 
most comprehensive in terms of time period, 
geographical coverage, and examined risk 
factors. The potential rate of opportunistic 
prostate cancer screening in the general 
population of men aged ≥40 makes data 
from the CAP trial9 complex to interpret. 
However, increased rates of opportunistic 
screening were significantly associated 
with black African and Caribbean ethnicity, 
increasing age, increased affluence, and 
family history of prostate cancer. There were 
also reduced rates in men with diabetes and 
smokers, as well as regional variation.
Strengths and limitations 
The major strength of this intentionally 
contemporaneous study is the use of 
the QResearch database. The very large 
representative cohort of >2.8 million men 
from across England had high-quality, 
accurately coded, individual-level data27 
with protracted follow-up and a low risk 
of bias related to selection, and recall. It 
also had linkages to enable the optimal 
ascertainment of interventions, diagnoses, 
deaths, and laboratory investigation results 
across the healthcare network.28,29
Limitations include the extent to which 
urinary tract symptoms have been recorded 
by GPs. This was mitigated to the best 
of the authors’ abilities by extracting data 
based on >100 Read codes, which indicate 
a comprehensive range of urinary tract 
symptoms. Other limitations of the study 
include information bias and missing data 
(such as for ethnicity).
Comparison with existing literature
Several studies have examined the rates 
of PSA testing in British men;17–21,30 
however, these comprise study cohorts 
smaller than those in the study presented 
here,20 have focused purely on single 
geographical regions,17 or have limited 
time frames.18,19,21,30 Other studies have 
identified similar associations between 
PSA testing and age, ethnicity, level of 
deprivation, and geographical region,19,20,30 
but none has examined as extensive a 
panel of covariates as the study presented 
here, or comprehensively assessed the 
associations with opportunistic prostate 
cancer screening.
Screening uptake was statistically 
significantly associated with previously 
established risk factors for prostate cancer 
diagnosis, including ethnicity and positive 
family history of prostate cancer.22 As such, 
the status quo of informal, opportunistic 
screening may be an inadvertent 
manifestation of a patient-led, risk-adapted 
strategy or one guided by some GPs.
Implications for practice
Men seeking PSA screening in general 
practice may not be uncommon, which gives 
a mandate for a deep awareness among 
clinicians of the benefits and harms of PSA 
screening, which is sometimes limited.19,31,32 
Predictors of screening uptake may be 
useful for the design of future screening 
strategies, and the data presented here may 
help give some context to findings of other 
studies regarding trends in prostate cancer 
incidence, stage at diagnosis, treatments, 
and mortality in the UK. 
The authors have identified factors 
rendering interpretation of the largest 
ever prostate cancer screening trial 
complex. Restricting the study focus to a 
contemporaneous sub-cohort matched by 
age range, it was estimated that 23% of such 
men in England would have had a screening 
test by 10 years’ follow-up; this would reduce 
the trial’s power to detect a difference 
in prostate cancer-specific mortality 
between screened and ‘non-screened’ 
arms (the power calculation has assumed 
a contamination rate of <20%). Statistical 
analyses adjusting for contamination and 
screening non-compliance33 in the CAP 
trial may be of great interest for screening 
policy, as has been done for the Prostate, 
Lung, Colorectal and Ovarian (PLCO) trial 
results,12,34,35 provided that they are clearly 
explained and robustly developed.36 
The results presented here suggest 
limited plausibility of deriving clear 
conclusions from trials of PSA screening. 
The notional conclusion that one-off 
PSA screening is not efficacious may be 
over-simplistic given the likely extent of 
contamination, possibly incorrect, or poorly 
reflective of a complex situation requiring 
nuanced interpretation. The CAP trial and 
the authors’ study were conducted in a 
population generally regarded as having a 
low uptake of opportunistic screening. Given 
the results of the authors’ study, it appears 
that, even in these settings, contamination of 
control arms may always occur, regardless 
of the geographical location and design of 
any PSA screening trial. This may bemire 
evidence-based practice. In conjunction with 
the low probability of new trials examining 
PSA alone as a screening modality, 
policymakers, researchers, clinicians, and 
patients should accept that we have entered 
a challenging ‘post-trial’ world.
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